Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...

The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...

Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Sage's board will look at a range of ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding proposal offer from biotech giant Biogen to acquire the remaining shares of ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...

Scotiabank lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps an Outperform rating on the shares. The firm’s ...

--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq ... Collaboration revenues represent 50% of the net revenues recorded when Biogen ships ZURZUVAE to the distributors. For the year ended December ...